Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific personnel transaction rather than a financial performance report.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document details a specific increase in the notional allocation of Ordinary share ADRs within a retirement plan due to a re-valuation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Type: Increase in notional allocation of Ordinary share ADRs within the US Retirement Savings Plan.
- Director Involved: Dr M M Slaoui (Connected Person: Dr K Slaoui).
- Transaction Date: June 24, 2011.
- Price: $41.34 per ADR.
- Quantity: 5 ADRs.
- Reason: Re-valuation of the cash element of the notional investment.